TY - JOUR
T1 - Effect of interstitial and/or systemic delivery of tirapazamine on the radiosensitivity of human glioblastoma multiforme in nude mice
AU - Cardinale, Robert M.
AU - Dillehay, Larry E.
AU - Williams, Jeffery A.
AU - Tabassi, Kevin
AU - Brem, Henry
AU - Lee, Ding Jen
PY - 1998/1/1
Y1 - 1998/1/1
N2 - The purpose of this study was to investigate the feasibility and the efficacy of administering tirapazamine by a slow-releasing polymer disc that was implanted interstitially into a U251 (human glioblastoma multiforme) tumor grown in nude mice. Tumorbearing animals, with a tumor nodule 0.8 cm3 in size, were distributed to groups receiving combinations of empty or drug-containing polymer implants in the tumor or contralateral leg, intraperitoneal (i.p.) drug, and/or irradiation. The drug (i.p.) alone (14 mg/kg ×6) or in combination with tumor drug implant (2 mg) did not significantly increase the tumor volume doubling time compared to that of control animals. Given with 12 Gy of irradiation in twice a day 2-Gy fractions, combined i.p. drug and tumor drug implant significantly delayed tumor growth compared to irradiation alone, which was not achieved with either drug treatment alone added to irradiation. Toxicity, as manifested by transient weight loss, was primarily seen in animals receiving radiation and i.p. tirapazamine. These results indicated that a slow-releasing tirapazamine disc can be produced and the addition of an interstitially implanted tirapazamine disc further increased the effectiveness of i.p. tirapazamine.
AB - The purpose of this study was to investigate the feasibility and the efficacy of administering tirapazamine by a slow-releasing polymer disc that was implanted interstitially into a U251 (human glioblastoma multiforme) tumor grown in nude mice. Tumorbearing animals, with a tumor nodule 0.8 cm3 in size, were distributed to groups receiving combinations of empty or drug-containing polymer implants in the tumor or contralateral leg, intraperitoneal (i.p.) drug, and/or irradiation. The drug (i.p.) alone (14 mg/kg ×6) or in combination with tumor drug implant (2 mg) did not significantly increase the tumor volume doubling time compared to that of control animals. Given with 12 Gy of irradiation in twice a day 2-Gy fractions, combined i.p. drug and tumor drug implant significantly delayed tumor growth compared to irradiation alone, which was not achieved with either drug treatment alone added to irradiation. Toxicity, as manifested by transient weight loss, was primarily seen in animals receiving radiation and i.p. tirapazamine. These results indicated that a slow-releasing tirapazamine disc can be produced and the addition of an interstitially implanted tirapazamine disc further increased the effectiveness of i.p. tirapazamine.
KW - Glioblastoma multiforme
KW - Hypoxic cell cytotoxin
KW - Implantable polymer disc
KW - Tirapazamine (SR 4233)
UR - http://www.scopus.com/inward/record.url?scp=0031924291&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031924291&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1520-6823(1998)6:2<63::AID-ROI1>3.0.CO;2-F
DO - 10.1002/(SICI)1520-6823(1998)6:2<63::AID-ROI1>3.0.CO;2-F
M3 - Article
C2 - 9572682
AN - SCOPUS:0031924291
SN - 1065-7541
VL - 6
SP - 63
EP - 70
JO - Radiation Oncology Investigations
JF - Radiation Oncology Investigations
IS - 2
ER -